Zacks Investment Research
17 Nov 2026, 16:46 UTC · 34m ago
J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts
Impact · against what's priced in
J&J's acquisition of Ollin Biosciences provides a concrete catalyst for the revenue acceleration the market currently declines to price in, particularly through the expansion of its ophthalmology pipeline. The deal's risk-sharing structure with Blackstone further protects margins, addressing a key market skepticism regarding the cost of growth.
- JNJ+0.50
Challenges what's priced in
- The price assumes
The $50 billion oncology sales target for 2030, which would demand a sustained acceleration in Innovative Medicine
The market is not yet paying for the acceleration of Innovative Medicine needed to reach long-term targets; adding a phase III asset like OLN324 for retinal diseases provides a specific growth lever to move beyond the current 6% growth rate.
What JNJ's price assumes · Sep 3





